The Oral Microbiota is Associated With Autoimmune Thyroiditis

The Oral Microbiota in Autoimmune Thyroiditis is Distinctive And Predictive

Sponsors

Lead Sponsor: First Affiliated Hospital of Harbin Medical University

Source First Affiliated Hospital of Harbin Medical University
Brief Summary

Autoimmune thyroiditis (AITD) mainly includes Hashimoto's thyroiditis (HT) and Grave's disease (GD). Studies have shown that autoimmune thyroiditis is closely related to microbial disorders such as autoimmune thyroiditis However, there is no report on the relationship between oral microecology and autoimmune thyroiditis. Therefore, our group will study the correlation between oral microbiota and AITD.

Detailed Description

Autoimmune thyroiditis (AITD) mainly includes Hashimoto's thyroiditis (HT) and Grave's disease (GD). Studies have shown that autoimmune thyroiditis is closely related to microbiological disorders. Intestinal microelements Both ecology and oral microecology belong to the category of microorganisms. It has been reported in the literature that intestinal microecology occurs disorder of autoimmune thyroiditis. However, there is no report on the correlation between oral microecology and autoimmune thyroiditis. When oral microbe flora When the immune system is disrupted, the immune balance is broken, the immune system is over-active, and the autoimmune disease (AID) is lost to the autoantigens and non-pathogenic commensal microbial flora antigens, including rheumatoid arthritis, Sjogren's syndrome, systemic lupus erythematosus, inflammatory bowel disease, and allergic diseases. However, the association between oral microbial flora and AITD remains unclear. . Therefore, the research group will carry out the correlation between oral microbial flora and AITD.

Overall Status Recruiting
Start Date 2017-12-23
Completion Date 2021-12-01
Primary Completion Date 2019-12-01
Study Type Observational
Primary Outcome
Measure Time Frame
Transcriptional changes in oral microbiota Baseline, 3 months, 6 months, 9 months, 12 months
Secondary Outcome
Measure Time Frame
Serum thyroid function changed Baseline, 3 months, 6 months, 9 months, 12 months
Enrollment 120
Condition
Intervention

Intervention Type: Drug

Intervention Name: Methimazole Pill

Description: Patients who developed GD received methimazole treatment

Arm Group Label: Drug treatment group

Intervention Type: Drug

Intervention Name: Propylthiouracil Pill

Description: Patients who developed GD received propylthiouracil treatment

Arm Group Label: Drug treatment group

Eligibility

Sampling Method:

Probability Sample

Criteria:

Inclusion Criteria: - Aged 18 to 65 years - GD was clinical diagnosed and thyroid function returned to normal - HT was clinical diagnosed and thyroid function is normal. Exclusion Criteria: - Pregnancy - Lactation - Cigarette smoking - Alcohol addiction - Hypertension - Diabetes mellitus - Lipid dysregulation - BMI > 27 - Recent (< 3 months prior) use of antibiotics, probiotics, prebiotics, symbiotics, hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or Chinese herbal medicine - History of disease with an autoimmune component, such as MS, rheumatoid arthritis, IBS, or IBD - History of malignancy or any gastrointestinal tract surgery

Gender:

All

Minimum Age:

18 Years

Maximum Age:

65 Years

Healthy Volunteers:

Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Yunwei Wei Study Director First Affiliated Hospital of Harbin Medical University
Overall Contact

Last Name: Yunwei Wei

Phone: +86-0451-85553099

Email: [email protected]

Location
Facility: Status: Contact: First affiliated hospital of Harbin medical university Yunwei Wei +86-0451-85553099 [email protected]
Location Countries

China

Verification Date

2017-12-01

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Arm Group

Label: Control group

Description: 30 healthy volunteers were included in the healthy control group

Label: Drug treatment group

Description: 30 GD patients who received treatment with Methimazole Pill or propylthiouracil pill

Label: Incipient group

Description: 30 untreated GD patients

Label: Hashimoto's thyroiditis group

Description: 30 HT patients

Patient Data No
Study Design Info

Observational Model: Case-Control

Time Perspective: Cross-Sectional

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News